Figure 2From: Detection of in vivo atherosclerotic plaque progression with a fibrin-targeted MR contrast agentCNR of plaques within the brachiocephalic arteries with molecular MRI pre- (grey) and 1.5 - 2 hours post (black) i.v. administration of EP-2104R (n = 5.9). All EP-2104R treated HFD groups show significant visual enhancement of plaques compared to non-contrast enhanced images and the control.Back to article page